Compound ID | 869
Class: Quinolone
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | More active against S. aureus, S. epidermidis, S. faecalis, S. pneumoniae, S. pyogenes, E. coli and B. fragilis than ciprofloxacin |
| Institute where first reported: | Upjohn Company (Pfizer, USA) |
| Year first mentioned: | 1991 |
| Highest developmental phase: | Preclinical |
| Development status: | Inactive |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/44373890 |
| Citations: |
|